Astellas Entered into a Research Collaboration and License Agreement with GO Therapeutics to Develop Novel Immuno-Oncology Therapies
Shots:
- GO to receive $20.5M up front, ~$763M in milestones & contingency fees. The companies collaborated to identify novel Abs with high affinity for 2 different glycoprotein targets & use these Abs in a variety of therapeutic approaches
- GO will be responsible to discover high-affinity Abs against 2 targets. Astellas will lead the research activities, clinical development & commercialization of the therapies that derived from the Abs
- The collaboration will combine GO's targets & Abs with Astellas' ACCEL technology for cancer treatments with a greater therapeutic index. Oncologists will be able to improve the efficacy of Abs-based immunotherapies for solid tumors while causing less harm to healthy tissues
Ref: PR Newswire | Image: Astellas
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
